<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01482936</url>
  </required_header>
  <id_info>
    <org_study_id>OXYI09-CN-101</org_study_id>
    <nct_id>NCT01482936</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic (PK) Study of OxyNorm Injections in Chinese Patient</brief_title>
  <official_title>A Single Dose PK Study of Oxycodone Hydrochloride Injection 2.5, 5, and 10mg in Chinese Patients With Cancer Pain or Post-operation Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mundipharma (China) Pharmaceutical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mundipharma (China) Pharmaceutical Co. Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center, open label, randomized, parallel group single dose intravenous
      (i.v.) administration study. The subjects will be randomized to receive a single dose of
      OxyNorm® 2.5, 5, and 10mg.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After up to 7 days screening period, Eligible Patients will be randomized to 1 of 3 groups,
      and begin treatment with single dose of OxyNorm® 2.5,5, and 10mg.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve (AUC) concentrations of oxycodone hydrochloride injection at various time points: predose, 0min, 2min, 5min, 10min, 15min, 30min, 45min, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24hr post dose.</measure>
    <time_frame>2 days</time_frame>
    <description>Plasma concentrations of oxycodone and Noroxycodone and Oxymorphone will be analyzed.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Oxycodone (OxyNorm®) Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subjects will be randomized to receive a single dose of OxyNorm® 2.5, 5, and 10mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone (OxyNorm®) Injection</intervention_name>
    <description>The subjects will be randomized to receive a single dose of OxyNorm® 2.5, 5, and 10mg.The plasma concentration will be analyzed to determine the following pharmacokinetic parameters:AUC0-t:ug•hr/L-Area under the plasma concentration-time curve frame: predose,0,2min,5min,10min,15min,30min,45min,1hr,1.5hr,2hr,3hr,4hr,6hr,8hr,12hr, 24hr post-dose.AUC0-inf:ug•hr/L-Area under the plasma concentration-time curve extrapolated to infinity. Cmax: ug/L-Maximum observed plasma concentration of oxycodone and noroxycodone.Tmax: hrs-time at which Cmax is first observed. t½: Apparent half life of oxycodone elimination.</description>
    <arm_group_label>Oxycodone (OxyNorm®) Injection</arm_group_label>
    <other_name>OxyNorm®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with tumor pain / postoperative pain, or subjects with pain caused by other
             diseases;

          -  Patients aged ＞30 to ≤ 60 years;

          -  Body weight ≥ 45kg, and BMI range ≥19, &lt;24;

          -  Karnofsky score ≥ 70;

          -  Expected survival is above 3 months;

          -  The results of liver function and kidney tests must meet the following
             criteria:ALT、AST is within the upper limit of normal value ranges by a factor 2, and
             TB、BUN、Cr is within the upper limit of normal value ranges by a factor 1.25;

          -  The electrocardiogram examination results are normal;

          -  Patients must have given a written informed consent prior to this trial, and have the
             capability to complete every required test.

        Exclusion Criteria:

          -  Have hypersensitivity history to any opioids;

          -  Have known hypersensitivity to any of compositions of the study drugs;

          -  Patients who are likely to have paralytic ileus or acute abdomen or to perform an
             operation on abdominal region；

          -  Patients with respiratory depression, cor pulmonary, or chronic bronchial asthma;

          -  Patient unable to stop taking monoamine oxidase inhibitor during this trial period or
             time lapses less than 2 weeks since drug withdrawal;

          -  Patients with hypercarbia;

          -  Patients with biliary tract diseases, pancreatitis, prostatic hypertrophy, or
             corticoadrenal insufficiency;

          -  Patients with alcoholism or drug abuse history;

          -  Positive ant-HIV or syphilis antibody test result;

          -  Urine screening before study is positive for the opioids, barbiturates, amphetamines,
             cocaine metabolites, methadone, diazepam and cannabinoids;

          -  Donated 400 mL or more of blood or blood products within 3 months prior to the start
             of the study, or donated 200 mL or more of blood or blood products within one month
             prior to the start of the study.

          -  Subjects who participated in a clinical research study within two months of study
             entry.

          -  Patients who are currently taking opioids.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mundipharma China Ltd.</last_name>
    <role>Study Chair</role>
    <affiliation>Mundipharma China Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site: Affiliated Hospital to Academy of Military Medical Science of China People's Liberation Army</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2011</study_first_submitted>
  <study_first_submitted_qc>November 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2011</study_first_posted>
  <last_update_submitted>August 10, 2015</last_update_submitted>
  <last_update_submitted_qc>August 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxycodone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

